11 results about "Hedgehog signalling" patented technology

Provided are: a method for producing a spinal cord organoid from a pluripotent stem cell in vitro, the method comprising (1) a step for culturing a human pluripotent stem cell in a culture medium that contains a ROCK inhibitor and a Wnt signal activator but does not substantially contain a TGFβ inhibitor or a BMP signal inhibitor, (2) a step for further culturing the cell obtained in step (1) in a culture medium that contains a retinoic acid receptor agonist and a hedgehog signal activator, and (3) a step for further culturing the cell obtained in step (2) in a culture medium that does not substantially contain a TGFβ inhibitor, a BMP signal inhibitor, a retinoic acid receptor agonist, or a sonic hedgehog stimulator to obtain a spinal cord organoid; and a spinal cord organoid obtained by the method. The spinal cord organoid according to the present application comprises at least a portion of the dorsal side of the spinal cord and a ventral region of the spinal cord.

The invention relates to a class of compounds useful as Hedgehog Acyltransferase inhibitors, as well as the treatment or prevention of diseases associated with the Hedgehog signalling pathway using the compounds of the present invention. In one aspect, the present invention provides a compound of formula (I) below.

The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the Hedgehog (Hh) signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof.

The invention relates to a method of generating endolymph-producing epithelial cells and in vitro use of a hedgehog signalling inhibitor for differentiation of inner ear progenitor cells into endolymph-producing epithelial cells; in vitro endolymph-producing epithelial cells and an inner ear organoid comprising endolymph-producing epithelial cells. Also provided is in vitro use of an inner ear organoid in drug discovery; the endolymph-roducing epithelial cells for use in a method of treating diseases of the inner ear; and a method of testing one of more therapeutic agents using these cells or organoids. Lastly, also provided is a kit and an organoid maturation medium.

To provide a novel inhibitor that can inhibit a Hedgehog signal even for a subject having SMO gene mutation.SOLUTION: A Hedgehog signal inhibitor includes a molecule targeting phosphorization of a serine residue at a position equivalent to position 252 of sequence number 1 in GLI2 having an amino acid sequence shown by sequence number 1 or an amino acid sequence identical to sequence number 1 by 90% or more, and / or a serine residue at a position equivalent to position 313 of sequence number 2 in GLI3 having an amino acid sequence shown by sequence number 2 or an amino acid sequence identical to sequence number 2 by 90% or more.SELECTED DRAWING: Figure 7

Described herein are compounds and pharmaceutical compositions containing such compounds for the modulation of Hedgehog signaling.

The application provides application of Hilnc (Hedgehog signal-induced long-chain non-coding RNA) or a signal pathway containing the Hilnc as a target for regulating lipid metabolism. The Hilnc plays an important role in Hh-mediated lipid metabolism. The Hh signal pathway and lipid metabolism are associated with lncRNAs for the first time in the application, which is an important progress in Hh signal transduction, lncRNAs, cell metabolism and lipid metabolism research.

A compound of Formula (I) for use in a method of treating pr preventing a disease associated with an aberrantly activated Hedgehog (HH) signalling pathway; Wherein A is selected from halo, or optionally substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, alkyl, alkenyl and alkynyl; B is an optionally substituted aryl or heteroaryl; L1 is absent or alkylene, NR’, NR’-alkylene, O, O-alkylene, S or S-alkylene; L2 is –(CR’2)0-3-C(O)NR’-, -(CR’2)1-3NR’-, -(CR’2)1-3NR’C(O)-, -C(=S)NR’-, -C(=NR’)NR’-, -S(O2)NR’-, -NR’C(O)NR’-, NR’S(O2)NR’, -OC(O)NR’-, -CR’F-NR’-, -CF2NR’-, -CR’(CF3)NR’-, -CF=CR’, -oxetane-NR’ and hetroarylene; X is N or CR5; R1 and R2 are each independently selected H, halo, alkyl, alkenyl, alkynyl and haloalkynyl, or together with the atoms to which they are attached form an aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R’, R3, R4 and R5 are as herein defined. Phramaceutical compositions comprising a subset of compounds of Formula (I) are also disclosed. B may be preferably phenyl, pyridyl pr thiophenyl.

The invention belongs to the technical field of biological medicines, and relates to a tetrahydropyridine [4, 3-d] pyrimidine derivative as a Hedgehog signaling pathway inhibitor and a preparation method thereof. The tetrahydropyridine [4, 3-d] pyrimidine derivative serving as a Hedgehog signal channel inhibitor is prepared by creatively adjusting the reaction temperature and the ratio of reactants to a catalyst, the reaction yield is greatly increased, the reaction conditions are mild, and the derivative serving as the Hedgehog signal channel inhibitor has good activity on pancreatic cancer cells and medulloblastoma.

Described herein are methods of promoting remyelination in a subject having a demyelinating disease by administering to the subject a combination of a steroid hormone and a Hedgehog signaling pathway modulator. Also described are methods of administering a combination of pharmaceutical products, wherein the combination of pharmaceutical products is in a composition suitable for nasal administration.